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Abstract 
Background: Biomarkers may contribute to improved cardiovascular risk estimation. Glycated hemoglobin  A1c 
 (HbA1c) is used to monitor the quality of diabetes treatment. Its strength of association with cardiovascular outcomes 
in the general population remains uncertain. This study aims to assess the association of  HbA1c with cardiovascular 
outcomes in the general population.
Methods: Data from six prospective population-based cohort studies across Europe comprising 36,180 participants 
were analyzed.  HbA1c was evaluated in conjunction with classical cardiovascular risk factors (CVRFs) for association 
with cardiovascular mortality, cardiovascular disease (CVD) incidence, and overall mortality in subjects without diabe-
tes (N = 32,496) and with diabetes (N = 3684).
Results: Kaplan–Meier curves showed higher event rates with increasing  HbA1c levels (log-rank-test: p < 0.001). Cox 
regression analysis revealed significant associations between  HbA1c (in mmol/mol) in the total study population and 
the examined outcomes. Thus, a hazard ratio (HR) of 1.16 (95% confidence interval (CI) 1.02–1.31, p = 0.02) for cardio-
vascular mortality, 1.13 (95% CI 1.03–1.24, p = 0.01) for CVD incidence, and 1.09 (95% CI 1.02–1.17, p = 0.01) for overall 
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Introduction
Assessing the cardiovascular risk in the general popula-
tion is important for clinical decision-making, including 
the prescription of medication or targeting of lifestyle 
intervention strategies [1–3]. Despite the identification of 
novel independent biomarkers, assessment of cardiovas-
cular risk relies on a set of traditional cardiovascular risk 
factors (CVRFs) such as age, sex, blood pressure, lipid 
levels, diabetes mellitus (DM), and smoking. The deci-
sion whether to include novel biomarkers in cardiovas-
cular risk assessment remains a topic of intense debate 
and research [4]. Diabetes is regarded as a classical risk 
factor for cardiovascular disease (CVD) [5]. Due to the 
clinical need to identify novel risk factors to improve 
cardiovascular risk assessment, glycated hemoglobin or 
hemoglobin  A1c  (HbA1c) may be a potential candidate [6]. 
The primary clinical use of  HbA1c is as an indicator of the 
average blood glucose levels over the past 3 months and 
thus it is used as a diagnostic and screening tool for DM 
[7, 8].
While associations between  HbA1c levels and the risk 
of cardiovascular outcomes or overall mortality have 
been reported [9–14], only few studies suggested that 
 HbA1c may be associated with cardiovascular outcomes 
in an apparently healthy population [9, 15–19]. Recently 
published results underlined the additional use of  HbA1c 
levels in middle-aged individuals without a history of 
CVD and  HbA1c levels in the nondiabetic range [1]. Stud-
ies employing Mendelian randomization support a link 
between increasing  HbA1c levels and an increased risk of 
coronary artery disease [20, 21]. In this context,  HbA1c 
might be associated with an increased risk and could be 
of importance in individuals without a diagnosis of dia-
betes [4].
In the present study, we evaluated the distribution of 
 HbA1c levels in population-based cohorts across Europe. 
Furthermore, we analyzed the association of continuous 
 HbA1c levels with cardiovascular mortality, CVD inci-
dence, and overall mortality. In addition, the association 
between  HbA1c levels and time-to-event was analyzed 
in subgroups with and without diabetes and according 
to age. Finally, cut-offs for the dichotomization of  HbA1c 
were determined for each outcome.
Methods
Study overview
The design and rationale of the Biomarker for Cardio-
vascular Risk Assessment across Europe (BiomarCaRE) 
project have been described previously [22]. Briefly, Bio-
marCaRE is based on the MORGAM (MONICA Risk 
Genetics Archiving and Monograph) Project. The MOR-
GAM/BiomarCaRE Data Center in Helsinki harmonized 
individual data from 21 population-based cohort studies 
with central storage of selected biomaterial of more than 
300,000 participants [22]. Using the harmonized data-
base of the BiomarCaRE project (FP7/2007–2013) [22], 
we analyzed individual data of 36,180 study participants 
with available  HbA1c levels.
Study cohorts
The present analysis included six cohort studies from 
four European countries (Germany, Italy, Sweden, and 
Norway), namely the Cooperative Health Research in the 
Region of Augsburg (KORA) Study, the Study of Health 
in Pomerania (SHIP), and the Epidemiologische Studie 
zu Chancen der Verhütung, Früherkennung und opti-
mierten THerapie chronischer ERkrankungen in der 
älteren Bevölkerung (ESTHER) Study, all from Germany, 
the MONICA Brianza Study from Italy, the Northern 
Sweden MONICA Study from Sweden, and the Tromsø 
Study from Norway. Each cohort is based on a well-
defined population (see Additional file 1: Table S1).
For each cohort, the following harmonized variables 
were available at baseline: duration of time with diag-
nosed diabetes in years, age, sex, smoking status, body-
mass-index (BMI), systolic blood pressure, diastolic 
blood pressure, total cholesterol, high-density lipoprotein 
(HDL) cholesterol,  HbA1c, and history of DM. The history 
mortality was observed per 10 mmol/mol increase in  HbA1c. The association with CVD incidence and overall mortal-
ity was also observed in study participants without diabetes with increased  HbA1c levels (HR 1.12; 95% CI 1.01–1.25, 
p = 0.04) and HR 1.10; 95% CI 1.01–1.20, p = 0.02) respectively.  HbA1c cut-off values of 39.9 mmol/mol (5.8%), 
36.6 mmol/mol (5.5%), and 38.8 mmol/mol (5.7%) for cardiovascular mortality, CVD incidence, and overall mortality, 
showed also an increased risk.
Conclusions: HbA1c is independently associated with cardiovascular mortality, overall mortality and cardiovascular 
disease in the general European population. A mostly monotonically increasing relationship was observed between 
 HbA1c levels and outcomes. Elevated  HbA1c levels were associated with cardiovascular disease incidence and overall 
mortality in participants without diabetes underlining the importance of  HbA1c levels in the overall population.
Keywords: Biomarkers, Glycated hemoglobin  A1c  (HbA1c), Cardiovascular risk, Mortality, BiomarCaRE (Biomarker for 
Cardiovascular Risk Assessment in Europe), MORGAM (MONICA Risk Genetics Archiving and Monograph)
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of DM was defined as documented or self-reported his-
tory of diabetes. This variable includes both type 1 and 
type 2 DM. Detailed definitions of this variable in each 
cohort are provided in Additional file  1: Table  S1. Also 
participants not diagnosed with DM but with high  HbA1c 
levels (> 48  mmol/mol/6.5%—a diagnostic criterion for 
clinical DM) were assigned to the DM group. Additional 
sub-classification into type 1 or type 2 DM was not pos-
sible with this dataset. Treatment of DM was available as 
(a) medication with insulin, (b) oral medication, but no 
insulin and (c) diet only.
Smoking status was determined based on self-reports. 
BMI, systolic blood pressure, diastolic blood pressure, 
total cholesterol, and HDL cholesterol parameters were 
measured (high blood pressure was defined either as sys-
tolic blood pressure ≥ 140 mmHg and/or diastolic blood 
pressure ≥ 90  mmHg) and it was recorded whether the 
patient was on antihypertensive medication. Prevalent 
CVD, like previous myocardial infarction or stroke, was 
assessed using the documented or self-reported history 
of myocardial infarction or stroke, including angina pec-
toris when the data did not permit its distinction from 
myocardial infarction. In MORGAM, prevalent heart 
failure was assessed with the item documented or self-
reported history of heart failure.
Study outcome
The following outcome measures were defined: (I) cardi-
ovascular mortality, (II) CVD incidence, and (III) overall 
mortality, defined as mortality due to any cause during 
follow-up. Follow-up commenced at the baseline exami-
nation date [23].
Cardiovascular mortality included death due to coro-
nary heart disease or stroke. Cardiovascular disease, as 
an endpoint, was defined as the first fatal or non-fatal 
coronary event or possible ischemic stroke. Coronary 
events included acute definite or possible myocardial 
infarction or coronary death, unstable angina pectoris, 
cardiac revascularization, and unclassifiable death (i.e., 
death with insufficient evidence of coronary origin and 
no competing cause). In the MONICA/KORA Augsburg 
study, cardiac revascularization was not followed-up. In 
the MONICA/KORA Augsburg and MONICA Brianza 
studies, unstable angina pectoris was not assessed as an 
outcome but primarily included in the category “possible 
myocardial infarction” of the WHO MONICA classifica-
tion used in these studies.
Laboratory procedures
HbA1c was measured using whole blood. All  HbA1c 
measurements were performed upon study entry to avoid 
glycation of blood samples during storage (except the 
Northern Sweden MONICA cohort measuring  HbA1c 
levels in samples that had been stored at − 80 °C). Locally 
measured  HbA1c values were transferred directly to the 
MORGAM Data Center (except for the SHIP study). The 
assays either reported their results as percentages (%), 
following the National Glycohemoglobin Standardiza-
tion Program (NGSP), or in units of mmol/mol if they 
had employed the International Federation of Clinical 
Chemistry (IFCC) consensus reference method. Data 
from cohorts which reported their values as percentages 
were converted to mmol/mol using the standard formula: 
IFCC = 10.93 * NGSP − 23.50.
Statistical analyses
Unadjusted and age-adjusted Kaplan–Meier survival 
curves for cardiovascular mortality, CVD incidence, 
and overall mortality were computed based on  HbA1c 
tertiles. For the age-adjusted Kaplan–Meier survival 
analyses the three  HbA1c tertiles were < 34.4  mmol/
mol (5.3%), 34.4  mmol/mol (5.3%) − 38.8  mmol/mol 
(5.7%); and > 38.8  mmol/mol (5.7%). To adjust the sur-
vival curves for the age distribution in the data, the fol-
lowing procedures were applied: (a) age was categorized 
using cut-offs 35, 40, 45, 50, 55, 60, 65, and 70 years; (b) 
an individual belonging to a particular  HbA1c tertile and 
to age category j was assigned a weight equal to  (nj/N)/
(nij/N), where N is the total sample size,  nj is the number 
of individuals in age category j, and  nij is the number of 
individuals in age category j belonging to the  HbA1c ter-
tile; (c) these weights were then applied to the observa-
tions for estimating the Kaplan–Meier curves. A log-rank 
test was used to compare the unadjusted survival curves. 
The adjusted survival curves we compared using a robust 
score test obtained from a weighted Cox model with 
 HbA1c categorized using tertiles as the only predictor. 
Follow-up time quartiles were estimated by the Kaplan–
Meier potential follow-up estimator [24].
Sex- and cohort-stratified Cox proportional hazards 
models for cardiovascular mortality, CVD incidence, 
and overall mortality were computed using individual-
level data from the available cohorts. For these analyses 
the  HbA1c (in mmol/mol) was applied untransformed 
and used as continuous variable. The Cox models for the 
three endpoints were adjusted for age (time scale), sex 
and cohort (strata), and CVRFs, smoking status (daily 
smoker yes/no), BMI, systolic blood pressure, DM (yes/
no), total cholesterol to HDL cholesterol ratio and treat-
ment of DM. Two separate extensions of the models were 
considered. In one extension, baseline age groups < 55, 
55–64, ≥ 65  years at baseline and their interaction with 
continuous untransformed  HbA1c was added to the 
models. In the second extension, an interaction between 
continuous untransformed  HbA1c and the group indica-
tor for diabetes was added. For these models results the 
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 HbA1c hazard ratios are presented in forest plots and 
tables. In the former  HbA1c hazard ratios are presented 
per 10 mmol/mol increase and in the later per 1 mmol/
mol increase (Additional file  1). To assess the linearity 
assumption of  HbA1c used in the previous Cox regres-
sions, additional Cox models with  HbA1c were for-
mulated using penalized cubic splines. C-indices were 
computed using these last models and compared against 
a model including all other predictors with the excep-
tion of  HbA1c. Further details are given in Additional 
file 1.  HbA1c cut-offs that intend to separate subjects into 
low- and high-risk groups were calculated for each end-
point using the method of Contal and O’Quigley [25]. 
This method examines a rescaled version of the log-rank 
test statistic for each possible cut-off and selects the cut-
off that maximizes the rescaled log-rank test statistic. 
Equality of survival curves in the groups separated by 
the optimal cut-off values was tested using the methods 
described by Contal and O’Quigley [25].
Individuals with CVD at baseline were excluded in the 
survival analyses using CVD as endpoint. There were no 
exclusions based on prevalent disease for the two other 
endpoints.
A two-sided P-value of < 0.05 was considered statisti-
cally significant. Adjustment for multiple testing was not 
performed due to the exploratory nature of the analyses 
[26]. All statistical methods were implemented in R sta-




The baseline characteristics for individuals with available 
 HbA1c measurements for the entire cohort and for indi-
viduals with and without DM are shown in Table 1. The 
characteristics of each cohort are summarized in Addi-
tional file 1: Table S2.
For 36,180 subjects,  HbA1c measurements and infor-
mation regarding diabetes status were available. Men and 
women were represented almost equally (19,111 women; 
52.8%). The median age was 57.4  years, the median 
BMI 26.4  kg/m2, and the median systolic blood pres-
sure 133.5 mmHg. At baseline, approximately 28% of the 
study cohort were daily smokers, 47.5% had high blood 
pressure or were taking antihypertensive medication, and 
10.2% had a diagnosis of diabetes.
Distribution of  HbA1c levels in the cohort
The distribution of  HbA1c levels in the entire cohort and 
each cohort study are shown in Additional file 1: Fig. S1. 
The median  HbA1c was 36.6 mmol/mol (5.5%). The 25th 
and 75th percentiles were 32.2  mmol/mol (5.1%) and 
39.9 mmol/mol (5.8%), respectively.
HbA1c levels and association with cardiovascular mortality, 
cardiovascular disease, and overall mortality
The maximum follow-up time was 21.9 years. During the 
median follow-up time of 9.9 years, 1392 cases of cardio-
vascular death, 2711 cases of CVD, and 4,601 deaths due 
to any cause were observed. Further information on the 
median follow-up for each cohort is provided in Addi-
tional file 1: Table S3.
As illustrated in the age-adjusted Kaplan–Meier sur-
vival analyses for the three  HbA1c tertiles < 34.4  mmol/
mol (5.3%), 34.4  mmol/mol (5.3%) − 38.8  mmol/mol 
(5.7%); and > 38.8 mmol/mol (5.7%) the probability of all 
investigated outcomes increased with increasing  HbA1c 
levels (Additional file 1: Fig. S2). Adjusting the curves for 
age reduced the separation between the curves (Fig. 1).
HbA1c‑associated risk in the overall cohort, age groups 
and individuals with and without DM
The fully adjusted hazard ratios (HRs) shows associa-
tions with cardiovascular mortality, CVD incidence, and 
overall mortality, with respective HR of 1.16 (95% confi-
dence interval (CI): 1.02–1.31, p = 0.02) for cardiovascu-
lar mortality, 1.13 (95% CI 1.03–1.24, p = 0.01) for CVD 
incidence, and 1.09 (95% CI 1.02–1.17, p = 0.01) for over-
all mortality per 10 mmol/mol increase in  HbA1c (Figs. 2 
and 3, Additional file 1: Table S4).
In individuals with DM, we observed a HR of 1.19 
(95% CI 0.97‒1.46; p = 0.1) for cardiovascular mortality, 
1.17 (95% CI 0.97‒1.40; p = 0.1) for CVD incidence, and 
1.08 (95% CI 0.95‒1.21; p = 0.24) for overall mortality. 
In participants without DM, the respective HRs for car-
diovascular mortality, CVD incidence, and overall mor-
tality were 1.14 (95% CI 0.98‒1.33; p = 0.1), 1.12 (95% CI 
1.01‒1.25; p = 0.04), and 1.10 (95% CI 1.01‒1.20; p = 0.02) 
(Fig. 2).
Following stratification according to age groups, the 
association between  HbA1c and risk of cardiovascu-
lar disease incidence was pronounced in individuals 
aged < 55  years (HR: 1.25, 95% CI 1.07 –1.46, p = 0.006) 
but diminished with increasing age. In this context, the 
results for the cohort with subjects older ≥ 55  years 
and < 65 years were (HR: 1.18, 95% CI 1.04–1.33; p = 0.01) 
and not present in individuals older 65  years (HR: 1.05, 
95% CI 0.93–1.19; p = 0.44) for cardiovascular disease 
(Fig. 3).
Dose–response relationships
Modelling the association of  HbA1c and time-to-event 
using cubic splines indicates a slightly curved increas-
ing association for the considered endpoints, with the 
exception of cardiovascular mortality where the curve 
decreases until approximately 33  mmol/mol (5.2%) 
(Fig.  4). The hypothesis of linearity of  HbA1c for all 3 
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endpoints could not be rejected (p = 0.087 for cardiovas-
cular mortality, p = 0.5 for CVD, and p = 0.56 for overall 
mortality).
Cut‑off value of  HbA1c for risk estimation
HbA1c cut-off values for cardiovascular mortality, CVD 
incidence, and overall mortality were calculated, yield-
ing 39.9  mmol/mol (5.8%), 36.6  mmol/mol (5.5%), and 
38.8 mmol/mol (5.7%), respectively. These cut-offs indicate 
an increased risk for the outcome. This is shown by the 
age-adjusted Kaplan–Meier curves for the three outcomes 
(Fig. 5). During follow-up, participants that were above the 
respective cut-off at baseline had a higher risk for each of 
the outcomes. The unadjusted Kaplan–Meier curves are 
shown in Additional file 1: Fig. S3.
Calculation of C‑indices
Calculation of C-indices showed no relevant improve-
ment in risk prediction by adding the  HbA1c level to the 
model including the baseline risk factors which were used 
for adjustment of the Cox regression models for the over-
all cohort and for individuals without diabetes (Additional 
file 1: Table S5).
Table 1 Baseline characteristics of the entire study population
Baseline characteristics are presented as absolute and relative frequencies for categorical variables, and quartiles (medians with 25th and 75th percentiles) for 
continuous variables as well as range in years for years of baseline examinations
The numbers provided for the cardiovascular disease endpoint are after excluding those individuals with history of cardiovascular disease
BMI body mass index, BP blood pressure, CHD coronary heart disease, HDL high density lipoprotein, LDL low density lipoprotein, MI myocardial infarction
All (N = 36,180) No diabetes (N = 32,496) Prevalent diabetes (N = 3684)
Baseline characteristics
 Survey year 1987–2012 1987–2012 1987–2012
 Examination age (years) 57.4 (47.0, 65.1) 56.4 (45.3, 64.5) 64.0 (57.9, 69.0)
 Male (%) 17,069 (47.2) 15,095 (46.5) 1974 (53.6)
 BMI (kg/m2) 26.4 (23.8, 29.4) 26.1 (23.6, 29.0) 29.2 (26.4, 32.6)
 Daily smoker (%) 8243 (27.7) 7602 (27.9) 641 (25.7)
 Hypertension (%) 17,084 (47.5) 14,506 (44.9) 2578 (70.6)
 Systolic BP (mmHg) 133.5 (120.0, 149.0) 132.0 (120.0, 147.0) 140.0 (130.0, 155.5)
 Diastolic BP (mmHg) 80.0 (74.0, 90.0) 80.0 (74.0, 89.5) 80.5 (76.0, 90.0)
 Antihypertensive (%) 7827 (21.7) 6057 (18.7) 1770 (48.5)
 Diabetes (%) 3684 (10.2) 0 (0) 3684 (100)
 Diabetes treatment: none (%) 33,834 (95.1) 32,496 (100) 1338 (43.5)
 Diabetes treatment: insulin (%) 598 (1.7) 0 (0) 598 (19.4)
 Diabetes treatment: tablets, but no insulin 
(%)
1007 (2.8) 0 (0) 1007 (32.7)
 Diabetes treatment: dietary (%) 133 (0.4) 0 (0) 133 (4.3)
 Family history of CHD (%) 4716 (18.6) 4242 (18.7) 474 (17.6)
 Prev. MI or stroke (%) 2132 (6.0) 1587 (4.9) 545 (15.3)
 History of MI (%) 1417 (4.0) 1060 (3.3) 357 (10.0)
 Prev. stroke (%) 862 (2.4) 624 (1.9) 238 (6.6)
 History of heart failure (%) 1454 (5.7) 1046 (4.7) 408 (13.2)
Endpoints
 Cardiovascular mortality (%) 1392 (3.9) 1080 (3.3) 312 (8.5)
 Cardiovascular disease (%) 2339 (8.2) 2043 (7.8) 296 (12.1)
 Overall mortality (%) 4601 (12.7) 3768 (11.6) 833 (22.7)
Biomarkers
  HbA1c (mmol/mol) 36.6 (32.2, 39.9) 35.5 (32.2, 38.8) 50.8 (44.3, 59.6)
  HbA1c (%) 5.5 (5.1, 5.8) 5.4 (5.1, 5.7) 6.8 (6.2, 7.6)
 Total cholesterol (mmol/L) 5.9 (5.0, 6.7) 5.9 (5.1, 6.8) 5.7 (4.8, 6.5)
 HDL cholesterol (mmol/L) 1.4 (1.2, 1.7) 1.4 (1.2, 1.7) 1.2 (1.0, 1.4)
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Discussion
Based on a fairly harmonized large-scale assessment of 
 HbA1c and cardiovascular outcomes, the present study 
has several main findings. First,  HbA1c levels were inde-
pendently associated with overall-mortality, cardio-
vascular mortality, and cardiovascular disease. Second, 
 HbA1c levels showed a mostly monotonically increasing 
association with all three outcomes. Third, the associa-
tion of  HbA1c with cardiovascular disease incidence was 
strongest in individuals younger than 55  years. Fourth, 
subgroup analyses based on diabetes status demonstrated 
that the association between  HbA1c and the examined 
outcomes were significantly associated with CVD inci-
dence and overall mortality in persons without diabe-
tes. Fifth,  HbA1c cut-off values were derived to define a 
threshold above which the risk of the examined outcomes 
was increased. Finally, despite significant associations of 
 HbA1c with the examined outcomes, 5-year prediction 
models were not significantly improved by the addition 
of  HbA1c on top of CVRFs.
HbA1c levels and the risk for cardiovascular outcomes
Although the presence of diabetes is a common risk 
factor for CVD, a continuous biomarker reflecting this 
risk factor is not currently used for risk assessment in 
the general population [6]. In the present prospective 
population-based study including 36,180 participants 
from six European countries, we demonstrated a mostly 
monotonically increasing association for cardiovascular 
mortality, CVD incidence, and overall mortality with 
increasing  HbA1c levels. The association was mostly 
monotonic and not J-shaped as reported before [28]. This 
is in line with a previous meta-analysis of individual level 
data which overall also did not find a J-shaped association 
[29]. While this study observed a J-shaped association of 
 HbA1c levels with all cause and cardiovascular mortality 
in one of the included studies [29] this seemed to be due 
to confounders like ethnicity, alcohol consumption, BMI, 
biomarkers of iron deficiency and liver function since the 
association of very low  HbA1c levels with mortality out-
comes lost statistical significance after adjusting for these 
confounders [29].
In this context, the current results with cut-off analy-
sis adjusted for age provided thresholds of  HbA1c 
levels being associated with cardiovascular disease, car-
diovascular mortality and overall mortality. These results 
underline the importance of  HbA1c levels below the 
threshold to diagnose diabetes and to identify individuals 
with an increased risk. Therefore, our findings underline 
previous statements from the American Diabetes Asso-
ciation [30] concerning the measurement of  HbA1c for 
cardiovascular risk assessment as well as the recent Euro-
pean Society of Cardiology 2019 guidelines [6] on adults 
without a diagnosis of diabetes. In this context, neither 
guideline defines prediabetes as a self-contained clini-
cal entity although individuals with prediabetes have an 
increased risk to develop diabetes or cardiovascular dis-
ease [6, 30, 31]. The American guidelines underline the 
Fig. 1 Age-adjusted Kaplan–Meier curves of A cardiovascular mortality, B cardiovascular disease, and C overall mortality for each  HbA1c tertile
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fact that prediabetes is associated with cardiovascular 
risk factors like obesity, arterial hypertension, and dys-
lipidemia and further that levels in the prediabetes range 
are associated with the risk to develop diabetes. The 
increasing risk for developing diabetes with increasing 
 HbA1c levels has been reported before [32]. Furthermore, 
the American guidelines [30, 31] also support the notion 
of including  HbA1c determination in clinical practice 
for prevention purposes to reduce future CVD burden. 
The results of the present study support this implica-
tion of using  HbA1c levels to identify individuals with an 
increased risk, e.g., classify them as prediabetic based on 
a cut-off value of > 38.8 mmol/mol (5.7%), especially since 
all our calculated cut-offs for subject differentiation were 
below the reported threshold to diagnose diabetes. The 
cut-off of > 38.8 mmol/mol (5.7%) is also in line with the 
threshold proposed by the American Diabetes Associa-
tion to define prediabetes in individuals without a diag-
nosis of diabetes [30, 31]. In the present study,  HbA1c 
levels above the cut-off value of 36.6  mmol/mol (5.5%) 
were associated with cardiovascular diseases. This under-
lines possible implications for levels below the cut-off 
value of  HbA1c used to diagnose prediabetes (i.e. 5.7%).
Fig. 2 Subgroup analysis comparing the association between  HbA1c and time-to-event in individuals with and without DM.  HbA1c was used as 
continuous variable in mmol/mol.  HbA1c hazard ratios are presented per 10 mmol/mol increase. The models include an interaction term between 
 HbA1c and the subgroup indicator (DM yes/no). The Cox models for the three endpoints were adjusted for age (time scale), sex and cohort 
(strata), and CVRFs, smoking status, BMI, systolic blood pressure, DM, DM treatment, and total cholesterol to HDL cholesterol ratio. The p-value for 
interaction is for an interaction between DM and  HbA1c
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A recent study in a smaller study population from 
Spain could also show the additional benefit of including 
 HbA1c levels for the association with CVD [1]. Extending 
the importance of  HbA1c levels in the clinical practice, 
additional data pointing out the usage of  HbA1c levels for 
risk stratification in patients with CVD or DM with an 
insufficient glucose control in patients from Asia should 
be noted [13, 14, 33, 34].
The recent study by Welsh and colleagues using data 
from the UK only with a median follow-up of 8.9  years 
also showed an association between  HbA1c levels and 
cardiovascular outcome [2]. The authors suggested that 
this risk may be increased due to a higher prevalence of 
CVRFs in the investigated population [2]. However, this 
interpretation stands in contrast to findings by a different 
article which showed that the cohort used in the Welsh 
et al. study had a lower prevalence of risk factors than the 
average UK population [35].
Age‑dependent effect of  HbA1c and risk for cardiovascular 
outcome
An important finding was that the association between 
 HbA1c and cardiovascular disease incidence was strong-
est in individuals aged under 55 years. This could imply 
Fig. 3 Hazard ratios for  HbA1c and outcomes: cardiovascular mortality, cardiovascular disease, and overall mortality, stratified into age groups. 
 HbA1c was used as continuous variable in mmol/mol. Hazard ratios are presented per 10 mmol/mol increase. The Cox models for the three 
endpoints were adjusted for age (time scale), sex and cohort (strata), and CVRFs, smoking status, BMI, systolic blood pressure, DM, DM treatment, 
and total cholesterol to HDL cholesterol ratio. The p-value for interaction is for an interaction between age groups and  HbA1c
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that young individuals with elevated  HbA1c levels may 
carry an additional risk for developing relevant cardio-
vascular disease. A possible causal link between  HbA1c 
levels and an increased risk of coronary artery disease 
was proposed in Mendelian randomization studies [20, 
21]. Although the analysis as presented was adjusted 
for the CVRFs the literature reports that these risk fac-
tors might have a different impact on the development 
of a cardiovascular outcome depending on the age of 
the individual [36]. Further, older individuals may be less 
affected by CVRFs since these were present without the 
individual developing an event prior to the baseline visit.
HbA1c measurement and its implication 
regarding the defined outcome
In this large European general population sample the 
association of  HbA1c with the risk of cardiovascular 
mortality, cardiovascular disease incidence, and overall 
mortality was mostly monotonic, considering the broad 
range of  HbA1c levels encountered in such large popu-
lation-based studies [2, 9, 15, 28, 37]. Considering this 
association, the recent definition of prediabetes [38], and 
the potentially higher risk of developing diabetes or car-
diovascular disease, additional clinical evaluation might 
be warranted in individuals with a higher risk profile. 
In our study, CVD incidence was associated with  HbA1c 
levels in participants without diabetes. In addition, the 
calculated cut-offs showing an elevated risk for over-
all mortality in individuals with > 38.8  mmol/mol (5.7%) 
highlights the importance of elevated  HbA1c levels and 
might indicate an increased risk for cardiovascular out-
comes and overall mortality. In the context of the current 
findings, previous studies reported a poor outcome for 
patients with coronary artery disease, atrial fibrillation or 
Fig. 4 Penalised cubic splines for the association between  HbA1c and time-to-event.  HbA1c was used as continuous variable and presented in 
mmol/mol
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individuals with DM and either cardiovascular risk fac-
tors or coronary artery disease [39–41]. However, it is 
not clarified if these findings are related to the rapid low-
ering of  HbA1c with multiple drugs [41] or due to its pro-
inflammatory, prothrombotic and proatherogenic effects 
reported in the setting of strict glucose control [42, 43].
It has to be pointed out that measurement of  HbA1c 
levels might be of benefit for identifying individuals with 
a high risk of developing DM and/or CVD, especially in 
the presence of risk factors such as obesity, dyslipidemia 
and/or arterial hypertension. In this context the Ameri-
can Diabetes Association recommends to measure  HbA1c 
levels in asymptomatic young adults [31].
Risk prediction models including  HbA1c levels
Inclusion of  HbA1c levels into assessment of risk predic-
tion regarding the defined outcomes did not show an 
improvement as reflected by C-indices. This is inline with 
previous reported results [2, 28].
Strengths and limitations
The present study has several strengths and limitations. 
An important strength is the considerable size of the 
dataset, with harmonized data from well-defined Euro-
pean population-based cohort studies with a long follow-
up time.
Despite the well-defined dataset, we identified 717 indi-
viduals with  HbA1c levels above 48 mmol/mol/6.5% that 
had not been diagnosed with diabetes. As the omission 
of such a sizable group may introduce considerable errors 
into our findings, we decided to classify individuals with 
 HbA1c levels above 48  mmol/mol/6.5% and without the 
diagnosis of diabetes as subjects with prevalent diabetes. 
An additional limitation is the heterogeneity of data. Sev-
eral cohort studies whose data we used commenced in 
the 1980s and 1990s, when treatment options and guide-
lines differed substantially from today’s. In population-
based cohort studies with apparently healthy individuals, 
selection bias is a common problem.
Haemoglobinopathies, different ethnicities, and certain 
disease states like bleeding, transfusion, or hemodialysis 
can interfere with the measurement of  HbA1c which may 
affect our results [38, 44].
Due to the absence of additional measures of dysgly-
cemia like 2-h post load glucose and fasting glucose we 
could not perform additional analyses to prove and to 
validate the prognostic impact of  HbA1c. These parame-
ters were reported to have a prognostic impact and might 
be better for risk stratification than  HbA1c [45, 46].
Conclusion
The present study employed one of the largest popu-
lation-based datasets with predominantly harmonized 
data on  HbA1c from several European countries.  HbA1c 
levels were positively associated with an increased 
risk for cardiovascular mortality, CVD, and overall 
Fig. 5 Age adjusted Kaplan–Meier curves for the outcomes A cardiovascular mortality, B cardiovascular disease, and C overall mortality based on 
the calculated cut-off values
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mortality. There was a mostly monotonically increas-
ing association between  HbA1c levels and time-to-
event regarding the defined endpoints cardiovascular 
mortality, cardiovascular disease incidence, and over-
all mortality, emphasizing the potential use of  HbA1c 
measurement as a biomarker in the general popula-
tion. Regarding risk stratification,  HbA1c levels could 
be particularly important in subjects with  HbA1c lev-
els > 38.8  mmol/mol (5.7%), indicating a potential 
prediabetic metabolism and potential risk of cardiovas-
cular disease. In addition, the findings might be of par-
ticular importance in individuals younger than 55 years 
who showed a more pronounced association of  HbA1c 
levels and cardiovascular mortality. However, the cost-
effectiveness of testing  HbA1c levels in an asymptotic 
general population needs further evaluation.
Further research and external validation in a clini-
cal setting are required to define whether an additional 
standardized measurement of  HbA1c is necessary for 
cardiovascular risk assessment.
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